Clinical Trial

Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Part 1 : To evaluate the safety of single-dose KK3910 in healthy volunteers. Part 2 : To evaluate the safety of multiple-dose KK3910 in patients with essential hypertension. Part 3 : To assess the safety profile of repeated dosing of KK3910 in an additional hypertension cohort.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-02-07; most recent amendment 2026-06-30.
Status change: Not Yet Recruiting → Recruiting 2025-04-30
Trial Details
NCT Number NCT06823947
Lead Sponsor Kyowa Kirin Co., Ltd.
Conditions Healthy Volunteers Essential Hypertension
Enrollment 160 participants
Start Date 2025-04-03
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-01